Adult Immunizations An Overview

October 26, 2018

Jennifer L. Frost, MD, FAAFP Medical Director, Health of the Public and Science American Academy of Family Physicians




Learning Objectives

- Know the immunizations routinely recommended for adults.
- Understand the burden of vaccinepreventable diseases.
- Identify resources to increase adult immunization rates.

Figure 1. Recommended immunization schedule for adults aged 19 years or older by age group, United States, 2018

This figure should be reviewed with the accompanying footnotes. This figure and the footnotes describe indications for which vaccines, if not previously administered, should be administered unless noted otherwise.

Vaccine	19–21 years	22–26 years	27-49 years	50–64 years	≥65 years						
Influenza ¹	1 dose annually										
Tdap ² or Td ²	1 dose Tdap, then Td booster every 10 yrs										
MMR ³	1 or 2 doses depending on indication (if born in 1957 or later)										
VAR4	2 doses										
RZV ⁵ (preferred)				2 doses RZV (p							
ZVL ^s					1 dose ZVL						
HPV–Female ⁴	2 or 3 doses depending										
HPV-Male ⁴	2 or 3 doses depending o	on age at series initiation									
PCV13'					1 dose						
PPSV237		dien	1 dose								
Hep A*		2 or	3 doses depending on vaco	Ine							
НерВ			3 doses								
MenACWY ¹⁰		1 or 2 doses depending o	n indication, then booster e	wery 5 yrs if risk remains							
MenB ¹⁰		2 01	3 doses depending on vaco	ine							
HID ¹¹		lori	i doses depending on indica	tion							



Recommended for adults with other indications

No recommendation

https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html

Measles, Mumps, Rubella

- Most adults born before 1957 considered immune
- Immunity established if
 - 1 documented MMR after
 12 months old if born after 1957
 - Titer
 - Born prior to 1957 (and not a HCW)

Measles, Mumps, Rubella

- High Risk:
 - Pregnancy
 - Immunosuppression
 - Healthcare worker
- Contraindications:
 - Pregnancy
 - Severe immunosuppression

Varicella (Chicken Pox)

- Immune to varicella if
 - Born before 1966
 - Confirmed infection '66-'97
 - Received vaccine
 - History of shingles
 - Varicella titer





Photo from <u>www.cdc.gov</u>. Image in public domain

Varicella

- High Risk:
 - Pregnancy
 - -HIV
 - Healthcare workers
- Contraindications:
 - Severe Immunodeficiency
 - Pregnancy

Influenza




Influenza Recommendation

- Universal seasonal vaccination for ALL persons ≥ 6 months of age
- High Risk Individuals include:
 - $-Age \ge 50$ years
 - Pregnancy
 - Chronic disease
- Effectiveness
 - Variable





Influenza Vaccination Percent vaccinated



www.cdc.gov/flu/fluvaxview/index.htm

Influenza Why Vaccinate

On average each year:

- 9.2 35.6 million illnesses
- 4.3 16.6 million medical visits
- 140,000 710,000 hospitalizations
- 12,000 56,000 deaths

Influenza Why Vaccinate

During the 2015-2016 flu season, the influenza vaccine prevented:

- > 5 million illnesses
- 2.5 million medical visits
- 71,000 hospitalizations
- 3,000 deaths

www.cdc.gov/flu/about/disease/2015-16.htm

Influenza Vaccines for older adults

- High dose trivalent (Fluzone high-dose)
- Trivalent with adjuvant (Fluad)
- LAIV only up to age 49 years



Influenza Vaccine Contraindications

- Severe hypersensitivity reaction to previous dose
- LAIV:
 - Severe egg allergy
 - Pregnancy
 - Immunosuppression

Influenza Myths

- The flu shot gives you the flu
- The flu shot doesn't work
- The flu shot isn't safe in pregnancy

Vaccine	19–21 years	22–26 years	27-49 years	50–64 years	≥65 years						
Influenza ¹		1 dose annually									
Tdap ² or Td ²		1 dose	Tdap, then Td booster every	10 yrs							
MMR ³		1 or 2 doses depend	ing on indication (if born in	1957 or later)							
VAR4	2 doses										
RZV ^s (preferred)		2 de	2 doses RZV (preferred)								
ZVL ^s					1 dose ZVL						
HPV-Fernale ⁴	2 or 3 doses depending	on age at series initiation									
HPV-Male ⁴	2 or 3 doses depending										
PCV13'				1.	dose						
PPSV23'		tion	1 dose								
Hep A ^a		20	r 3 doses depending on vaco	Ine							
HepB ^o			3 doses								
MenACWY ¹⁰		1 or 2 doses depending o	on indication, then booster e	wery 5 yrs if risk remains							
MenB ¹⁰		20	r 3 doses depending on vacc	ine							
нь		1 or 3	I doses depending on Indica	tion							
	age requirement, la	adults who meet the ick documentation of evidence of past infection	Recommended fo	r adults with other	No recommenda						

Figure 1. Recommended immunization schedule for adults aged 19 years or older by age group, United States, 2018 This figure should be reviewed with the accompanying foctnotes. This figure and the footnotes describe indications for which vaccines, if not previously administered, should be administered unless noted otherwise.

https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html

Tetanus/Diphtheria/Pertussis Recommendation


- One lifetime dose of Tdap for all individuals ≥ 10 years of age
- Td every 10 years

• One dose of Tdap during every pregnancy

Tetanus/Diphtheria

- Tetanus
 - Rare in U.S.
 - High Risk:
 - Adults \geq 65 years
 - Using I.V. drugs
- Diphtheria

Pertussis



www.cdc.gov/pertussis/surv-reporting.html

Pertussis

Immunize adults who have contact with infants



Tdap

- Children get five doses of DTaP before age 7, one dose Tdap age 11-12
- Adacel
 R
 aged 11 to 64 years
- Boostrix ® aged 10 or older

Tdap Vaccine Contraindications

- Severe hypersensitivity reaction to previous dose
- Severe latex allergy
- History of encephalopathy (coma, decreased level of consciousness, or prolonged seizures) not attributable to another identifiable cause within 7 days of a dose of pertussis vaccine

Figure 1. Recommended immunization schedule for adults aged 19 years or older by age group, United States, 2018

This figure should be reviewed with the accompanying footnotes. This figure and the footnotes describe indications for which vaccines, if not previously administered, should be administered unless noted otherwise.

Vaccine	19–21 years	22–26 years	27–49 years	50–64 years	≥65 years							
influenza ¹	1 dose annually											
Tdap ² or Td ²		1 dose Tdap, then Td booster every 10 yrs										
MMR ³		1 or 2 doses depending on indication (if born in 1957 or later)										
VAR4	2 doses											
RZV ⁵ (preferred)		2 doses RZV (preferred)										
ZVL ^s					or 1 dose ZVL							
HPV–Female ⁶	2 or 3 doses depending	on age at series initiation										
HPV-Male ^s	2 or 3 doses depending	on age at series initiation										
PCV13'				4	1 dose							
PPSV23 ⁷		1 or 2	tion	1 dose								
HepA ^s		2 or	3 doses depending on vacd	ine								
HepB ^o			3 doses									
MenACWY ¹⁰		1 or 2 doses depending o	n indication, then booster e	very 5 yrs if risk remains								
MenB ¹⁰		2 or	3 doses depending on vacc	ine								
HID ¹¹		1 or 3	doses depending on indica	tion								



Recommended for adults who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection

Recommended for adults with other indications

No recommendation

https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html

Human Papillomavirus Recommendation

- Gardisil-9
- Routine vaccination age 11-12 (2 doses)
- Give up to age 26 if not previously vaccinated (3 doses if given age 15-26)
- Approved by FDA up to age 45
- High Risk: Sex

Human Papillomavirus Why Vaccinate?

- Every year there are ~12,000 cases of cervical cancer and ~ 4,000 deaths from cervical cancer
- Gardisil protects against the most common causes of cervical cancer
- HPV also causes oral, vaginal, anal, penile cancer

Human Papillomavirus Vaccine Contraindications

- Severe hypersensitivity reaction to previous dose
- History of severe hypersensitivity to yeast

Human Papillomavirus Myths

- HPV vaccination does not promote sexual activity
- HPV vaccination should be given regardless of whether sexually active
- HPV vaccination should be given even if history of HPV infection

Figure 1. Recommended immunization schedule for adults aged 19 years or older by age group, United States, 2018


This figure should be reviewed with the accompanying locinotes. This figure and the footnotes describe indications for which vaccines, if not previously administered, should be administered unless noted otherwise.

Vaccine	19–21 years	22–26 years	27-49 years	50-64 years	≥65 years							
influenza'	1 dose annually											
Tdap² or Td²		1 dose	Tdap, then Td booster every	10 yrs								
MMR ³		1 or 2 doses depending on indication (if born in 1957 or later)										
VAR4	2 doses											
RZV ⁵ (preferred)				2 de	oses RZV (preferred) or							
ZVL ^s					1 dose ZVL							
HPV-Fernale ⁴	2 or 3 doses depending											
HPV-Male ^s	2 or 3 doses depending on age at series initiation											
PCV13 ⁷	1 dose											
PP5V23'	1 or 2 doses depending on Indication											
Hep A [#]		2 or	3 doses depending on vaca	Ine								
HepB ^o			3 doses									
MenACWY ³⁰		1 or 2 doses depending o	n Indication, then booster e	very 5 yrs if risk remains								
Men B ¹⁰		2 or	3 doses depending on vacd	ine								
нь"		1 or J	I doses depending on indica	tion								
		adults who meet the ick documentation of	Recommended for indications	r adults with other	No recommenda							

https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html


Pneumococcus

- Most common cause of pneumonia, ear infections, and meningitis in young children
- Pneumococcal pneumonia is most common pneumococcal disease in adults
- 90% of cases of invasive pneumococcal disease in adults ≥ 65



Pneumococcus

Trends in invasive pneumococcal disease among adults aged ≥65 years old, 1998–2016



*PPSV23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F *PCV13 serotype: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F

www.cdc.gov/pneumococcal/surveillance.html

Pneumococcal Vaccine Adult indications

Age 65 and older

Immunosuppression Lung disease Asplenia CV disease Liver disease Resident of long-term care facility Diabetes CSF leak Tobacco Chronic alcoholism Cochlear Implants

Pneumococcal Vaccine Recommendation

- Two vaccines recommended
 - PCV13
 - Children < 2 years
 - Adults \geq 65 years
 - PPSV23
 - One year after PCV13

Pneumococcus Vaccine Contraindications

 Severe hypersensitivity reaction to previous dose

Figure 1. Recommended immunization schedule for adults aged 19 years or older by age group, United States, 2018

This figure should be reviewed with the accompanying footnotes. This figure and the footnotes describe indications for which vaccines, if not previously administered, should be administered unless noted otherwise.

Vaccine	19–21 years	22–26 years	27–49 years	50–64 years	≥65 years							
influenza ¹	1 dose annually											
Tdap ² or Td ²		1 dose Tdap, then Td booster every 10 yrs										
MMR ³		1 or 2 doses depending on indication (if born in 1957 or later)										
VAR4	2 doses											
RZV ⁵ (preferred)				20	loses RZV (preferred)							
ZVL ^s					1 dose ZVL							
HPV–Female ⁶	2 or 3 doses depending											
HPV-Male ^s	2 or 3 doses depending	on age at series initiation										
PCV13'					dose							
PPSV23 ⁷	1 or 2 doses depending on indication											
Hep A ^s		2 or	3 doses depending on vacc	ine								
HepB ^o			3 doses									
MenACWY ¹⁰		1 or 2 doses depending o	n indication, then booster e	very 5 yrs if risk remains								
MenB ¹⁰		2 or	3 doses depending on vacc	ine								
HID ¹¹		1 or 3	doses depending on indica	tion								



Recommended for adults who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection

Recommended for adults with other indications

No recommendation

https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html

Herpes Zoster Recommendation

- 2 vaccines now available
 - Zoster Live Vaccine (Zostavax)
 - One dose adults \geq 60 years of age
 - Recombinant Zoster Vaccine (Shingrix)
 - 2 dose 2-6 months apart for adults ≥ 50 years of age
 - Preferred
 - Current shortage


Herpes Zoster Why Vaccinate

- ~1 million cases of shingles every year
- 32% of Americans will experience a Zoster outbreak during their lifetime
- 1 out of 5 patients with Zoster get post-herpetic neuralgia



Herpes Zoster

FIGURE 3. Rate* of zoster and postherpetic neuralgia (PHN)[†], by age — United States



www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm?s_cid=rr5705a1_e#fig3

Herpes Zoster Effects of Postherpetic Neuralgia

Physical	Psychological
 Chronic fatigue 	Anxiety
 Anorexia & weight loss 	 Difficulty concentrating
 Physical inactivity 	 Depression, suicidal ideation
• Insomnia	
Social	Functional
 Fewer social gatherings 	 Interferes with activities of daily
 Change in social role 	living: dressing, bathing, eating,
	travel, cocking, shopping
Schmader KE. Clin Infect Dis2001;32(10):1481-	6

Schmader KE. Clin Infect Dis2001;32(10):1481-6

Herpes Zoster Vaccine Contraindications

- Severe hypersensitivity reaction to previous dose
- Current shingles
- Pregnancy or breastfeeding

Herpes zoster Myths

- The shingles vaccine can cause shingles
- I don't need the shingles vaccine if I haven't had chicken pox

Barriers

- Many adults don't realize they need them
- We get distracted by chronic illnesses during busy visits
- Adult recommendations are often riskbased (more complicated)
- Coverage/Cost

STRONG RECOMMENDATION Strong Recommendation Strong Recommendation Strong Recommendation STRONG RECOMMENDATION STRONG RECOMMENDATION Strong Recommendation

STRONG RECOMMENDATION Strong Recommendation

STRONG RECOMMENDATION Strong Recommendation

Increase adult immunization rates

• Easy access to immunization schedules




141144	-	1 80	104	+148	++++	100	10-05	11-000	10100	14.01	++++	+++1	1-0.00	11.1414	18-18-00	16.61	1116,
Number of pages	-				•		-		-								1
Second di 000 persona anna 102-1 merchio			-	-	talla.												
Particle Insta Assolute				-	1.44		5. 13	•				1.44					
revealable privities sports Long			-	1164	-	-	- 21	1					-	-			
Point			-	-	-	1	• •						2			1	1
matrixed scheme: (FIT-118,pc)			-	-			****	_	-		-	***	0		14-00		
Marrie Wi								-									
					(ite be	****	• •					-					
searcher (ends)												1.000					
-								-	1100.0		-	=	-	-	-	_	
NUMBER AND A					_	(line in	-									-	
Riberto, deletioning, & monitory (participate) (charges of physical						-								-			
mergeneet?						-					-	-			Children of		
PROVIDENT														-			




Increase adult immunization rates Resources for providers

- http://www.immunize.org/guide/
- <u>https://www.cdc.gov/vaccines/pubs/pinkbook/index.h</u> <u>tml</u>
- <u>https://www.cdc.gov/vaccines/hcp/adults/for-practice/standards/index.html</u>







Increase adult immunization rates Resources for patients

- AAFP's FamilyDoctor.org
 - https://familydoctor.org/immunizations/
- CDC website
 - https://www.cdc.gov/vaccines/index.html
- Immunization Action Coalition
 - http://www.immunize.org/handouts/

